Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: Transarterial chemoembolization plus atezolizumab and bevacizumab in patients with intermediate hepatocellular carcinoma: a single-arm, phase 2 trial

Fig. 2

Waterfall plot showing the percentage maximum change from baseline in the sum of the longest diameter of target lesions in each of the 45 patients, according to treatment response per RECIST v1.1 criteria. RECIST, Response Evaluation Criteria in Solid Tumors. Dotted lines represent the definition of partial response and progressive disease per RECIST v1.1 criteria. * The partial response was not sustained for two consecutive assessment cycles

Back to article page